{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:54:01Z","timestamp":1773338041467,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170151"],"award-info":[{"award-number":["82170151"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["232300420238"],"award-info":[{"award-number":["232300420238"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.leukres.2025.108114","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:16:58Z","timestamp":1759249018000},"page":"108114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Multicenter retrospective analysis of the short-term efficacy and safety of the VAH regimen in the treatment of acute myeloid leukemia"],"prefix":"10.1016","volume":"159","author":[{"given":"Ruihua","family":"Mi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.leukres.2025.108114_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2025.108114_bib2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2025.108114_bib3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2025.108114_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106317","article-title":"Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: a multicenter retrospective study","volume":"91","author":"Lou","year":"2020","journal-title":"Leuk. Res"},{"issue":"2","key":"10.1016\/j.leukres.2025.108114_bib5","first-page":"134","article-title":"[Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience]","volume":"43","author":"Yu","year":"2022","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"10","key":"10.1016\/j.leukres.2025.108114_bib6","first-page":"861","article-title":"[Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia]","volume":"42","author":"Zong","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"3","key":"10.1016\/j.leukres.2025.108114_bib7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"11","key":"10.1016\/j.leukres.2025.108114_bib8","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3324\/haematol.2019.242826","article-title":"Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis","volume":"105","author":"Bewersdorf","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.leukres.2025.108114_bib9","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1002\/ajh.25567","article-title":"Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"94","author":"Aldoss","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2025.108114_bib10","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","article-title":"Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML","volume":"5","author":"Stahl","year":"2021","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.leukres.2025.108114_bib11","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(13)70152-9","article-title":"Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial","volume":"14","author":"Jin","year":"2013","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2025.108114_bib12","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-15-1191","article-title":"Targeting of BCL2 family proteins with ABT-199 and homoharringtonine reveals BCL2- and MCL1-Dependent subgroups of diffuse large B-Cell lymphoma","volume":"22","author":"Klanova","year":"2016","journal-title":"Clin. Cancer Res"},{"issue":"8","key":"10.1016\/j.leukres.2025.108114_bib13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.21037\/atm-22-1459","article-title":"Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms","volume":"10","author":"Yuan","year":"2022","journal-title":"Ann. Transl. Med"},{"issue":"1","key":"10.1016\/j.leukres.2025.108114_bib14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-023-01437-1","article-title":"Venetoclax combined with azacitidine and homoharringtonine in Relapsed\/Refractory AML: a multicenter, phase 2 trial","volume":"16","author":"Jin","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2025.108114_bib15","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00277-025-06250-z","article-title":"Efficacy of venetoclax combined with homoharringtonine and cytarabine for younger adults with newly diagnosed AML","volume":"104","author":"Song","year":"2025","journal-title":"Ann. Hematol."},{"issue":"20","key":"10.1016\/j.leukres.2025.108114_bib16","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2025.108114_bib17","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.leukres.2025.108114_bib18","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-Azacitidine induces NOXA to prime AML cells for Venetoclax-Mediated apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"8","key":"10.1016\/j.leukres.2025.108114_bib19","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat. Cancer"},{"issue":"17","key":"10.1016\/j.leukres.2025.108114_bib20","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","article-title":"Binding of released bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells","volume":"22","author":"Niu","year":"2016","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.leukres.2025.108114_bib21","doi-asserted-by":"crossref","first-page":"27696","DOI":"10.1038\/srep27696","article-title":"Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.leukres.2025.108114_bib22","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1158\/1535-7163.MCT-05-0164","article-title":"Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells","volume":"5","author":"Tang","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.leukres.2025.108114_bib23","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1073\/pnas.1818539116","article-title":"Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-\u03baB repressing factor","volume":"116","author":"Chen","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"15","key":"10.1016\/j.leukres.2025.108114_bib24","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1182\/blood.2023020102","article-title":"Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML","volume":"142","author":"Xie","year":"2023","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625006046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625006046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:21:07Z","timestamp":1773300067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625006046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":24,"alternative-id":["S0145212625006046"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108114","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicenter retrospective analysis of the short-term efficacy and safety of the VAH regimen in the treatment of acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108114"}}